Introduction
============

Retinitis pigmentosa (RP) is a heterogeneous group of retinal dystrophies, characterized by progressive degeneration of the photoreceptors. Clinical features include progressive night blindness, constriction and gradual loss of the peripheral visual field, and eventual loss of visual acuity. With an incidence of 1 in 3,500, RP can be inherited as an autosomal recessive (arRP), an autosomal dominant (adRP), or an X-linked recessive (xlRP) pattern \[[@r1],[@r2]\].

RP can be classified as syndromic and nonsyndromic RP, based on whether or not extra-ocular diseases exist. Nonsyndromic arRP is caused by the mutations of 32 identified genes \[[@r1],[@r2]\]. Syndromic RP includes more than 30 different syndromes \[[@r1],[@r2]\]. The most common syndrome is Usher syndrome (USH), which is also an autosomal recessive disorder characterized by sensorineural hearing loss, variable vestibular dysfunction, and visual impairment due to retinitis pigmentosa \[[@r2],[@r3]\]. Clinically, USH is subdivided into three types: USH type I (USH1), USH type II (USH2), and USH type III (USH3). USH1 is the most severe form of this disease and is characterized by congenital profound hearing loss, prepuberal onset of RP, and vestibular dysfunction. Patients with USH2 experience congenital moderate to severe hearing impairment, and postpuberal onset of RP with intact vestibular function. Patients with USH3 show progressive postlingual hearing loss, later onset of RP, and variable vestibular dysfunction. Of the three clinical types, USH2, which accounts for more than half of all patients with USH, is the most common form of USH \[[@r2]-[@r4]\]. To date, reports indicate that three genes (*USH2A* \[Usher syndrome type −2A protein\], *GPR98* \[G-protein coupled receptor 98\], and *DFNB31* \[CASK-interacting protein CIP98 isoform 1\]) are responsible for USH2, and most USH2 patients have mutations in *USH2A* \[[@r3]-[@r9]\].

*USH2A*, located on chromosome 1q41, has two alternatively spliced isoforms: a short *USH2A* isoform a, consisting of 21 exons, and a long *USH2A* isoform b, consisting of 51 additional exons at the 3′ end of *USH2A* \[[@r5],[@r9]\]. The protein usherin, encoded by USH2A isoform b, is a transmembrane protein, which has 5,202 amino acids \[[@r9]\]. The usherin is transiently expressed in the stereocilia of cochlear hair cells, suggesting an important role in their maturation \[[@r4],[@r9]-[@r11]\]. In mammalian photoreceptors, the usherin is expressed specifically in the connecting cilia, which links the inner and outer retinal segments; this would appear to indicate that it is crucial for the long-term maintenance of photoreceptors \[[@r9]-[@r11]\].

Since identification of *USH2A*, several studies have indicated that mutations of this gene can cause a significant proportion of non-syndromic recessive RP \[[@r12]-[@r20]\].

This study investigated a Chinese family with non-syndromic arRP. After haplotyping analysis, the disease-causing gene was mapped to the *USH2A* region. Mutations screening of the *USH2A* gene, corresponding to the *USH2A* isoform b, was then performed in this nonsyndromic RP family and in three USH2 families. Seven novel mutations were identified.

Methods
=======

Clinical data and sample collection
-----------------------------------

This study adhered to the tenets of the Declaration of Helsinki for research involving human subjects. The Beijing Tongren Hospital Joint Committee on Clinical Investigation approved the study. One Chinese family with nonsyndromic RP and three unrelated Chinese families with USH were referred to Beijing Tongren Hospital. After informed consent was obtained, each participant underwent careful ophthalmologic examinations, including best-corrected visual acuity testing using E decimal charts, slit-lamp biomicroscopy, fundus examination with dilated pupils, visual field testing, and electroretinogram (ERG) examination. Three probands from the three families with USH underwent audiometric testing, including otoscopy and standard pure-tone audiometry, and vestibular tests. The patients with nonsyndromic arRP were given audiometric tests after the disease gene was mapped to chromosome 1q41, where the *USH2A* gene is located. Clinical diagnosis of USH2 was based on the clinical history, typical RP fundus appearance, sensorineural hearing impairment, and intact vestibular function. Peripheral blood was obtained by venipuncture, and genomic DNA was extracted according to standard phenol protocols.

Genotyping and haplotyping analysis
-----------------------------------

Genotyping was performed with 50 microsatellite markers from autosomes for the known arRP loci in family FR1 ([Appendix 1](http://www.molvis.org/molvis/v17/a172/app-1.pdf)). Then, genotyping and haplotyping analysis was performed with another six microsatellite markers - D1S237, D1S419, D1S556, D1S229, D1S227, and D1S2860 - around the *USH2A* gene. The fine mapping primer sequences were obtained from the Human Genome Database ([GDB](http://www.gdb.org)). Pedigree and haplotype maps were constructed using [Cyrillic V. 2.0 software](http://www.cyrillicsoftware.com).

Mutation screening of the USH2A gene
------------------------------------

Mutation screening was performed in all four families using direct DNA sequence analysis. The coding region (exons 2--72) and the exon-intron boundaries of *USH2A* were amplified by PCR in the probands of the four families. The pairs of primers for exons 2--72 were used according to previously published ([Table 1](#t1){ref-type="table"}) articles \[[@r5],[@r9],[@r21]\]. For direct sequencing, amplicons were purified (Shenneng Bocai PCR purification kit; Shenneng, Shanghai, China). An automatic fluorescence DNA sequencer (ABI, Prism 373A; Perkin Elmer, Foster City, CA), used according to the manufacturer's instructions, sequenced the purified PCR products in both the forward and reverse directions. Nucleotide sequences were compared with the published cDNA sequence of the *USH2A* gene ([GenBank](http://www.ncbi.nlm.nih.gov/genbank/) [NM_206933.2](http://www.ncbi.nlm.nih.gov/gene?term=NM_206933.2)). For *USH2A*, cDNA numbering +1 corresponds to A in the ATG translation initiation codon in [RefSeq](http://www.ncbi.nlm.nih.gov/RefSeq/) ([AY481573.1](http://www.ncbi.nlm.nih.gov/ertrez/viewer.fcgi?db=nuccore&id=44887472)).

###### Primer information for the USH2A gene sequencing.

  **Primer**   **Forward sequence (5′-3′)**   **Reverse sequence (5′-3′)**   **Products (bp)**   **Tm (°C)**
  ------------ ------------------------------ ------------------------------ ------------------- -------------
  Exon 2       GCCTGGGATGAGCTTCAG             GGTTTGGAATTCAGGCTGA            840                 62
  Exon 3       CACCACTGTAACTGCACAATACC        CTGCTGCAGATTTTGTGAGTAGA        345                 64
  Exon 4       GTCTTCCCAGCTGAACAAAGTA         GTGGTAATTTGTTCAGTAGCCCTAG      382                 60
  Exon 5       GTCAGGTATTGCTTGGTAAACAG        CAGCATTTATCCTTTCGGTTC          173                 62
  Exon 6       CGAGTGACATTCATTTGTAACGA        GGCATTTGTTGCAATAACCA           437                 58
  Exon 7       TTTGAATCTAATAATTCCATGGTTTG     TGGTGGTGAAGGGAAGTCTC           372                 58
  Exon 8       CAACATTTTGATTTCTGTTTTGC        TGCTCTGACATCTTAATGTGCT         370                 62
  Exon 9       CACACAATGCATATAGTCCTAGG        TGTTAGGCCAAGATTAAGTTCAT        267                 62
  Exon 10      TGATATGTGCTTTACTTCTGGTG        GCATTGTAGATAGAAGCACACAG        356                 62
  Exon 11      TGGCAGGTAGAGATGAAAGG           GCAAATGCAGTCTTCAATTCTAC        371                 62
  Exon 12      CCCTGTCTTGTACCTAATGAGC         TTCCAGATGGTAATAGAGATGTGA       323                 62
  Exon 13      GCAGTAGCATTGTTTGTGTCTC         GTAGAAGCCACAAACCAGAAAC         816                 58
  Exon 14      GGGAATTAGTGCCTTGGTAGAG         GAAGTTATTGCTTTGCAACTGC         379                 64
  Exon 15      AAGCCGTCTTACTCTACAATGCT        TTCTGATGGGTTCTAAATGGAG         360                 58
  Exon 16      GCAATCCTGAATCAGAAAGACC         CCACAACAGCATTTATCCTCAA         354                 64
  Exon 17      GAGAGGAAAGCAGTTAGCAATG         GATTCTCATTCATGTCTTGACCA        626                 64
  Exon 18      AAGTAACCCCTTTGTCTGATGAGT       GGAAACATTTGCATTCAGAGG          378                 62
  Exon 19      TCAGAAACTAAATGAATGTGTGA        TGCCCTGTTTAATCAATATAGAG        379                 60
  Exon 20      TGGTGGTTGGCAATAATTCC           GAGTTAGTGAGGGAGGAGAAGACA       381                 64
  Exon 21      AGCCATACAGATACTTGAAACC         GCTATCAAAGGGCTGAATTAG          501                 62
  Exon 22      CCATGCGAGTATATTGCTGTG          GCTGAGGGCAAGTCACATTAC          451                 62
  Exon 23      CAGGAAAGCCAGAATGATGC           CCCAAAGGCAAATTCAACAG           447                 58
  Exon 24      CAGGCAATGAGGAGAGAGGA           CCTAAAGGAAATTTTTGGCACA         371                 58
  Exon 25      TGAATCATTAAGAGGCTTGCAG         TGTGTGCACCATTGGAATAAC          459                 58
  Exon 26      GGTCTTTCTGTCACTTCTGTGC         TTCAGTTATCAGGCGTGGTG           722                 62
  Exon 27      TGCTTTCAGGGAACTGTTTTG          GGTGCTGCTTTTAGCCTGAG           497                 62
  Exon 28,29   TGCTGCAGAGGACAAAAATG           GCTTCAGGGTAATAGTCCTTCC         579                 62
  Exon 30      TGCGGCCATTAAAAGTGAAG           TGCAGGCTTCCACTACTTTAG          434                 58
  Exon 31      GCAGAAAGGGAGGAAAATGAC          CAAATTAGGTTGGGGTTTGC           392                 64
  Exon 32      TGATTTATTGGTTTGGGTCTG          GCATTCTTGATTAAATTTGCAG         357                 58
  Exon 33      TGAAGCATCCTATATGTTATTGC        CCTCCCCTGATTGAACTCAC           392                 58
  Exon 34      ATTTCCTTTTTGCCCCTCAG           AGGATGGGAAGAGAGTTTTCAG         512                 56
  Exon 35      TTGGGGAAGTAAAGGTAGCAC          CCACAATCTCCCCAACTAGAG          431                 62
  Exon 36      AAATCACATCAAGAGTGCTTGC         CCTGCTTGAAAGGCTAGCTG           352                 62
  Exon 37      TGTGCTTTGATCCTGCTGAC           AACCAACATCTGTGGCTAAAAG         431                 60
  Exon 38      AATTGGCCAGGTCAACTCAG           TGTGAGGTGGATGAAAGCAG           614                 64
  Exon 39      CAGGAGTTCAGGAATGAAAATG         AAGTTTCAGTGGGAAGAAATCC         526                 54
  Exon 40      GAGATCTCATTTGATGGCAGAA         GGCTCATTTCTTTGCTTTGG           373                 58
  Exon 41      TGGCCTTTACCAAGTGTTCA           AAGGCCAAAACCCAGTTTCT           890                 54
  Exon 42      GCAAAATTCTAGGCCTCGTG           AAAGCCTCCTTCATTTCCCTAC         492                 62
  Exon 43      ATGCCACAGAACAGCCTGAG           AGCCGTGACAAAGGCAATAG           469                 62
  Exon 44      TTTTGTAGAGGGGTGGAAGG           TGTGTACATGGGGGAGGTTC           367                 58
  Exon 45      CATTTCCAAAACAAAGGCTCTC         TTAGCCTCCACCCCCTTC             464                 58
  Exon 46      TCATCATATCCCACTGGTCAC          CCCTTCTCTCTTTTCCCTTCC          599                 54
  Exon 47      AGGGAAGGTGGGATTCAGAC           TGTCATGGCTGAGAGGATACC          280                 59
  Exon 48      CCTCACGCCATGTGTTATTC           CCTTTCTTTTCCGTGGAGTC           530                 54
  Exon 49      TCGAATGATCCTGGAAAATACA         TTGTTGAGAGGGAGGTGTTTG          432                 56
  Exon 50      ACCTGTAAGTTGCCATGTGTG          TTTGGAGGACATGACCTTTTC          678                 54
  Exon 51      ATTTCAGCAACTGCCTGAGC           AAAGCTTCCCTGAGAACAGC           552                 62
  Exon 52      TGGGAAGCTGCAAAACTG             GGCCTCAAAGTATGATGGAATG         564                 54
  Exon 53      TCCGTATCCCTGCATCT              GGTTAGATGCATAGGGCAAT           500                 56
  Exon 54      ATTGCATTTCTTCCGAACAC           TCTCTCCTTCCAGCCATAGG           428                 54
  Exon 55      AAAGGGAAATGCTTCTCCAAG          CCCCCTAACCACAATGACAG           396                 62
  Exon 56      AGCCTCTTATGAGGTTCAGACC         CAAGCCTGAAGAATGGGAAC           422                 54
  Exon 57      GGGGATGGTGTGACTTTTG            ATGGCCAATGAATGAGGAAG           382                 56
  Exon 58      GGCAAAGAGTTTGCAATTTGTC         TTTATCCAGGAGACCGACTATG         399                 62
  Exon 59      CAAACATTTGTTGCCCATTC           GCCAGACTGTGATTTTTCTGG          488                 54
  Exon 60      TGCAAAAGGACAGGTTAAAA           GATTCTGCTGTGTTGGAGCA           343                 54
  Exon 61      TGACACCAGGAAGAAACAGC           TTATCCCCGTGACTACATTGC          638                 54
  Exon 62      TTTGGCCATGAGGTTCAGAG           TGAAGGGAGTTTTCCCACAG           417                 60
  Exon 63-A    AGGTTAAAAAGGGGCTAAGT           GGATATCACAGGTGGAGAGAGA         600                 54
  Exon 63-B    ATTCAGCTGGGCATACCTGT           CCATTGTCCAGGCAGATTTT           591                 59
  Exon 63-C    GAATGGAGGTTGCACAGCTA           GGCTCAGGCAATAGAAAGGTC          600                 58
  Exon 64      AATCTCGGCTCACTGCAAG            AGTGCCTTTTCAAATTGTGC           602                 62
  Exon 65      TGCTTTTGGTTGCCAATTTC           ACCGTAGAGCAACTGAGAACAG         440                 58
  Exon 66      TGTAGGAGGTGGGATCTTGG           CTGGGGAGTGCCAGGTAG             445                 60
  Exon 67      GAGCAGTTTCCTGCAAATGG           TCCCCACAAGAAAATCCTTC           579                 56
  Exon 68      GTTTGGATTGGTTCGGTTTG           CGTAAAGCTGGGGAACAGAG           344                 60
  Exon 69      CGTCATAACTTGCTTTGGAATC         CAACACTTGGCACAATTTCTTC         338                 60
  Exon 70      ATCAAATAGCAGGGCCAGAG           CCTCTCTTGGTCCCCACAC            462                 60
  Exon 71      GCTGCTAAATTCTGTAGGTGACA        TAAGTGCTCAGAGGCGAGTG           499                 56
  Exon 72      TGAGGCTTCTGAGGCTTAG            CTGCCAAACAGAACCAAGTG           651                 58

Restriction fragment length polymorphism analysis
-------------------------------------------------

Variations (c.2802T\>G, c.8232G\>C, c.3788G\>A, and c.14403C\>G) found in the sequencing were confirmed with the restriction endonucleases Hinc II (TaKaRa, Dalian, China), HpyCH4V, BsaI, and SpeI (New England Biolabs, Ipswich, MA), respectively, which were used in all available family members and in the100 normal controls.

Single strand conformation polymorphism
---------------------------------------

To validate the variations (c. 1876C\>T and c.7123delG) found in the sequencing, a single strand conformation polymorphism (SSCP) analysis was performed in all available family members and in the 100 normal controls. As the PCR fragments used in SSCP analysis were between 150 and 300 bp, two pairs of specific primers were designed for detecting mutations in exon 11 and exon 38 ([Table 2](#t2){ref-type="table"}).

###### Primers used in single strand conformation polymorphism (SSCP), high resolution melt curve analysis (HRM), and PAGE (PAGE) analysis in this study.

  **Primer**   **Sequence (5′-3′)**
  ------------ ---------------------------
  U11 SSCP     F: TGATGCAGGAAGGAACTGTG
  U11 SSCP     R: CCTGGCAAATGCAGTCTTC
  U32 HRM      F: ATCCCTTCCCAGTTCTTTG
  U32 HRM      R: CAGATATGGAACCCCTGGAT
  U38 SSCP     F: AATTGGCCAGGTCAACTCAG
  U38 SSCP     R: GCACCCAAAGGTTTGTCTC
  U48 PAGE     F: TGGTATCCATGCGCTAAAAC
  U48 PAGE     R: CACTTGGAGTCTTGAGTGAGAA

Abbreviations: U represents USH2A; the number represents the name of the exon; F represents forward; R represents reverse.

High-resolution melt curve analysis
-----------------------------------

To confirm the variation (c.6249delT) found in the sequencing, a high-resolution melt curve analysis (HRM) was performed in the available family members and in the 100 normal controls. Primer sequences were designed to obtain the best HRM performance, avoiding hairpin and primer--dimer formation as much as possible, and keeping the amplicon length under 250 base pairs. One pair of specific primers was designed for detecting a mutation in exon 32 ([Table 2](#t2){ref-type="table"}). The 10 μl reaction mixture consisted of 5 μl SsoFast EvaGreen Supermix (Bio-Rad Laboratories, Hercules, CA), 1 μl genomic DNA (10--150 ng/μl), 0.5 μl forward primer (10 pmol/μl), 0.5 μl reverse primer (10 pmol/μl), and 3 μl double distilled water. PCR cycling and an HRM analysis were performed on the Rotor-Gene 6000^TM^ (Corbett Research, Mortlake, NSW, Australia) \[[@r22]\].

Bioinformatics analysis
-----------------------

Garnier-Osguthorpe-Robson ([GOR](http://biotools.umassmed.edu/cgi-bin/biobin/garnier)) software was used to predict the effect of the mutation on the secondary structure of USH2A \[[@r23]\]. This method infers the secondary structure of a sequence by calculating the probability for each of the four structure classes (helix, sheet, turn, and loop), based on the central residue and its neighbors from the calculated matrices \[[@r23]\].

Results
=======

Clinical findings
-----------------

This study identified one Chinese family, consisting of four patients and one unaffected relative, diagnosed with non-syndromic RP, and three unrelated Chinese families, including four patients and six unaffected relatives diagnosed with USH2. The inheritance pattern in the families was autosomal recessive ([Figure 1](#f1){ref-type="fig"}). All the patients had experienced night blindness and vision acuity impairment. The patients with USH2 had hearing impairment in early childhood. Ophthalmoscopic examination demonstrated attenuation of the retinal vessels, bone-spicule pigmentation in the fundus, and waxy pallor of the optic nerve head ([Figure 2](#f2){ref-type="fig"}). The wave amplitudes of the ERG of the probands were indistinguishable from the baseline. Audiometric tests indicated moderate to severe sensorineural hearing impairment in the patients with USH2; in contrast, the results from the patients with non-syndromic arRP were normal. Vestibular functions of all the patients were normal. The detailed clinical information for each family's proband is summarized in [Table 3](#t3){ref-type="table"}.

![The pedigrees of the four Chinese families with autosomal recessive retinitis pigmentosa (arRP) or Usher syndrome type II (USH2), and with mutations in the *USH2A* gene. Pedigree and haplotyping analyses of family one (FR1) showed segregation with six microsatellite markers on chromosome 1 listed in descending order from the centromeric end. Squares indicate males; circles indicate females; slashed symbols indicate deceased; solid symbols indicate affected; open symbols indicate unaffected; and arrow symbol indicates proband. The genotype of each evaluated individual is shown below the individual's symbol and identification number. Abbreviations: Wild type (W); p.C934W (M1); p. W2744C (M2); p. R626X (M3); p. I2084fs (M4); p. W1263X (M5); p. D3165fs(M6); p.G2375fs (M7); p.Y4801X (M8).](mv-v17-1537-f1){#f1}

![The appearance of the fundus in two patients with non-syndromic retinitis pigmentosa (RP) or Usher syndrome type II (USH2). **A**: Fundus appearance of patient 077066 from family one (FR1), shows typical retinal degeneration with attenuation of the retinal vessels, irregular pigment clumps in the retina, and waxy pallor of the optic nerve head. **B**: Fundus appearance of patient 019092 from family F8.](mv-v17-1537-f2){#f2}

###### Clinical features of the probands from the four Chinese families with retinitis pigmentosa (RP) or Usher syndrome type II (USH2)

  **Family number**   **Proband**   **Best corrected visual acuity (R/L)**   **Oneset age of night blindness (year)**   **Fundus appearance**   **Oneset age of hearing loss (year)**   **Hearing impairment**   **Cataract**   **Visual field**   **ERG**             **Vestibular function**
  ------------------- ------------- ---------------------------------------- ------------------------------------------ ----------------------- --------------------------------------- ------------------------ -------------- ------------------ ------------------- -------------------------
  FR1                 077006        0.4/0.4                                  25                                         RP                      Normal hearing                          Normal                   Both eyes      N/A                Wave undetectable   Normal
  F6                  073001        0.5/0.4                                  13                                         RP                      5                                       Moderate(sp)             No             N/A                N/A                 Normal
  F7                  019082        1.0/1.0                                  17                                         RP                      1                                       Moderate(sp)             No             10°                N/A                 Normal
  F8                  019092        0.6/0.6                                  12                                         RP                      8                                       Moderate(sp)             No             10--15°            Wave undetectable   Normal

Abbreviations: R represents right eye; L represents left eye; SP represents slight progressive; N/A represents data not available.

Genotyping results
------------------

Family FR1 was genotyped with 50 polymorphic markers around the known arRP loci. The mapping results excluded the other known arRP loci with the exception of the *USH2A*. Further genotyping and haplotyping analysis for the six markers (D1S237, D1S419, D1S556, D1S229, D1S227, and D1S2860) suggested that the *USH2A* gene might be the disease-causing gene in this family ([Figure 1](#f1){ref-type="fig"}).

Mutation analysis
-----------------

Sequencing of the *USH2A* gene revealed 17 sequence variants in this study, eight of which were pathogenic mutations ([Table 4](#t4){ref-type="table"}). All eight pathogenic mutations were heterozygous; seven of them were first detected in the current study ([Figure 3](#f3){ref-type="fig"} and [Table 4](#t4){ref-type="table"}). Using RFLP, SSCP, or HRM analysis, the eight mutations co-segregated with the RP/USH2 phenotype, respectively ([Figure 4](#f4){ref-type="fig"}, [Figure 5](#f5){ref-type="fig"}, [Figure 6](#f6){ref-type="fig"}). Analyses did not detect the other seven mutations in the 100 normal controls, with the exception of p.C934W, which was identified in its heterozygous state in two individuals among the 100 normal controls ([Table 4](#t4){ref-type="table"}).

###### Disease-causing mutations in the Usher syndrome type IIA (USH2A) gene identified in this study

  **DNA change**          **Exon**   **Protein change**   **Type of nucleotide change**   **Family number**   **Frequency**   **Source**
  ----------------------- ---------- -------------------- ------------------------------- ------------------- --------------- ------------
  c.2802T\>G              13         p.C934W              Heterozygous                    FR1                 2/200           This study
  c.8232G\>C              42         p.W2744C             Heterozygous                                        0/200           This study
  c.1876C\>T              11         p.R626X              Heterozygous                    F6                  0/190           \[[@r24]\]
  c.6249delT              32         p.I2084fs            Heterozygous                                        0/200           This study
  c.3788G\>A              17         p.W1263X             Heterozygous                    F7                  0/200           This study
  c.9492_9498delTGATGAT   48         p.D3165fs            Heterozygous                                        0/200           This study
  c.7123delG              38         p.G2375fs            Heterozygous                    F8                  0/200           This study
  c.14403C\>G             66         p.Y4801X             Heterozygous                                        0/200           This study

The "Frequency" column, shows the number of chromosomes.

![A direct sequencing analysis of the coding region of the Usher syndrome type IIA (*USH2A*) gene. **A**: Sequence presents the heterozygous missense mutation c.2802T\>G (p.C934W) detected in patient 077006. **B**: Sequence shows the heterozygous missense mutation c.8232G\>C (p.W2744C) identified in patient 077006. **C**: Sequence presents the heterozygous nonsense mutation c.1876C\>T (p.R626X) identified in patient 073001. **D**: Sequence shows the heterozygous nonsense mutation c.3788G\>A (p.W1263X) detected in patient 019082. **E** shows the heterozygous, one-base-deletion mutation c.6249delT (p. I2084fs) in patient 073001; **F** is the corresponding wild-type sequence. **G** presents a heterozygous 7 bp deletion mutation c.9492_9498del TGATGAT (p. D3165fs) in patient 019082; **H** shows the corresponding wild-type sequence. **I** presents the heterozygous, one-base-deletion mutation c.7123delG (p. G2375fs) in patient 019092; **J** shows the corresponding wild-type sequence. **K**: Sequence shows the heterozygous nonsense mutation c.14403C\>G (p. Y4801X) detected in patient 019092.](mv-v17-1537-f3){#f3}

![A restriction fragment length analysis of the four mutations detected in this study. **A**: c.2802T\>G abolished a HincII restriction site that co-segregated with the affected individuals and the carriers (42 bp, 57 bp, 99 bp, 717 bp, and 774 bp), but not with unaffected individuals and normal controls (42 bp, 57 bp, and 717 bp). **B**: c.8232G\>C created a new HpyCH4V restriction site that co-segregated with the affected individuals and the carriers (88 bp, 186 bp, 218 bp, and 274 bp), but not with unaffected individuals and normal controls (218 bp, 274 bp). **C**: c.3788G\>A abolished a BsaI restriction site that co-segregated with the affected individuals and the carriers (70 bp, 132 bp, 422 bp, and 492 bp), but not with unaffected individuals and normal controls (70 bp, 132 bp, and 422 bp). **D**: c.14403C\>G created a SpeI restriction site that co-segregated with the affected individuals and the carriers (145 bp, 300 bp, and 445 bp), but not with unaffected individuals and normal controls (445 bp). A participant identification number is given above each lane. N represents normal controls.](mv-v17-1537-f4){#f4}

![A single-strand, conformation, polymorphism analysis and a 16% denaturing polyacrylamide gel electrophorese analysis. **A**: Single strand conformation polymorphism (SSCP) analysis for the heterozygous mutation c. 1876C\>T revealed that the mutant pattern (four bands) co-segregated with the affected individuals and carriers, but not with the unaffected individuals and normal controls (three bands). **B**: SSCP analysis for c.7123delG showed that the mutant pattern (three bands) co-segregated with the affected individuals and carriers, but not with the unaffected individuals and normal controls (two bands). **C**: 16% denaturing polyacrylamide gel electrophorese analysis for the heterozygous mutation c.9472_9498delTGATGAG (p. D3165fs) revealed that the mutant pattern (two bands) co-segregated with the affected individuals, but not with the unaffected individuals and normal controls (one band). Participant identification numbers are listed above each lane and N represents the normal controls.](mv-v17-1537-f5){#f5}

![A high-resolution, melt curve analysis (HRM) for the mutation c.6249delT (p. I2084fs) in family F6. In the amplicon, there is a SNP [rs6657250](http://www.ncbi.nlm.nih.gov/snp?term=rs6657250), c.6317T\>C, as marked in the plot. **A**: A difference plot for the five members in family F6. The median green, straight line presents the normal control with c.6317T\>C. The real-time PCR products of the family members are compared to the median normal control to produce the plot. The curve revealed that the mutant pattern (area within the rectangle) co-segregated with the affected individuals 073001, 073004, and carriers, 073003, but not with the unaffected individuals 073002, 073005, and normal controls c.6317T/T or c.6317C/C. **B**: Direct sequencing analysis shows the heterozygous, one-base-deletion mutation c.6249delT (p.I2084fs) in patients 073001 and 073004 and in the carrier 073003; sequences in individuals 073002 and 073005 are the wild type.](mv-v17-1537-f6){#f6}

Four different combinations of heterozygous mutations were detected in the four families. In family FR1 (non-syndromic arRP), two missense mutations, c.2802T\>G (p.C934W) and c.8232G\>C (p.W2744C), were detected in different alleles of patient 077006 ([Figure 1](#f1){ref-type="fig"}, [Figure 3](#f3){ref-type="fig"}, [Figure 4](#f4){ref-type="fig"}). Using the GOR method, the results for secondary structure prediction suggested that p.C934W replaced two β sheets "E" with two coils "C" at amino acids 935 and 940, respectively. Mutation p.W2744C substituted a β sheet "E" and two turn sheets "T" for three coils "C" at amino acid 2745, 2747, and 2748, respectively ([Figure 7](#f7){ref-type="fig"}). For the three USH2 families (F6, F7, and F8), one allele carried nonsense mutations, c.1876C\>T (p.R626X), c.3788G\>A (p.W1263X), and c.14403C\>G (p. Y4801X), respectively, while the other allele harbored deletion mutations c.6249delT (p. I2084fs), c.9492_9498del TGATGAT (p. D3165fs), and c.7123delG (p. G2375fs), respectively ([Figure 1](#f1){ref-type="fig"}, [Figure 3](#f3){ref-type="fig"}, [Figure 4](#f4){ref-type="fig"}, [Figure 5](#f5){ref-type="fig"}, [Figure 6](#f6){ref-type="fig"}).

![The effect of p.C934W and p. W2744C on the secondary structure of the USH2A using the GOR method. W denotes wild type, M denotes mutant.](mv-v17-1537-f7){#f7}

In addition to the eight pathogenic mutations detected in this study, nine nonpathogenic sequence variants were also identified. [Table 5](#t5){ref-type="table"} summarizes these variants based on their nature and frequency.

###### Presumed nonpathogenic variants of the Usher syndrome type IIA (USH2A) gene found in this study.

  **Exon**   **Nucleotide change**   **Codon**   **rs number**                                                   **Family number**   **Allele frequency**   **Source**
  ---------- ----------------------- ----------- --------------------------------------------------------------- ------------------- ---------------------- ---------------------------------------------------------------------------------
  2          c.373A\>G               p.A125T     [rs10779261](http://www.ncbi.nlm.nih.gov/snp?term=rs10779261)   F6                  N/A                    \[[@r14]\]
  3          c.504A\>G               p.T168T     [rs4253963](http://www.ncbi.nlm.nih.gov/snp?term=rs4253963)     F7                  267/720                \[[@r20]\]
  21         c.4457A\>G              p.K1486R    [rs1805049](http://www.ncbi.nlm.nih.gov/snp?term=rs1805049)     F7                  76/180                 \[[@r24]\]
  28         IVS27--34delC                       [rs71556647](http://www.ncbi.nlm.nih.gov/snp?term=rs71556647)   FR1                 N/A                    \[[c](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ss.cgi?subsnp_id=98581905)\]
  32         c.6317T\>C              p.I2106T    [rs6657250](http://www.ncbi.nlm.nih.gov/snp?term=rs6657250)     FR1,F6,F7,F8        N/A                    \[[@r29]\]
  34         c.6506T\>C              p.I2169T    [rs10864219](http://www.ncbi.nlm.nih.gov/snp?term=rs10864219)   FR1,F8              27/100                 \[[@r15]\]
  48         IVS48+78C\>T                                                                                        FR1                 N/A                    This study
  52         c.10232A\>C             p.E3411A    [rs10864198](http://www.ncbi.nlm.nih.gov/snp?term=rs10864198)   FR1                 23/64\*                \[[@r27]\]
  63         c.12612G\>A             p.T4204T    [rs2797235](http://www.ncbi.nlm.nih.gov/snp?term=rs2797235)     FR1,F8              N/A                    \[[@r27]\]

Abbreviations: N/A represents data not available; the asterisk indicates that the allele frequency referred to patients.

Discussion
==========

This study detected eight different mutations of the *USH2A* gene isoform b in one non-syndromic arRP family and in three USH2 families. Scandinavian, French, European, and Canadian studies \[[@r12],[@r14],[@r16],[@r24]-[@r26]\] previously reported the nonsense mutation p.R626X. The remaining seven mutations were first identified in this study.

Rivolta et al. first reported that about 4.5% of 225 patients from North America with non-syndromic recessive RP carried the missense mutation p.C759F \[[@r12]\]. Then, Bernal et al. found that there was a similar detecting frequency (4.6%) for p.C759F in Spanish patients \[[@r13]\].Two novel missense mutations, p.C934W and p.W2744C, were found in family FR1. Although p.C934W was identified (in a heterozygous state) in two individuals among the 100 normal controls, both mutations have been classified as deleterious-effect missense mutations with several lines of evidence. Both mutations co-segregated with the phenotype of family FR1 and both residues (C934 and W2744), located in the 8th Lam EGF domains and in the 14th FN3 repeat of the usherin, respectively, were highly conserved in different species ([Figure 8](#f8){ref-type="fig"}). The results of GOR suggested that p.C934W and p.W2744C lead to secondary structure changes around residues 934 and 2744, which might interfere with the correct folding of the usherin ([Figure 7](#f7){ref-type="fig"}). As the results of audiometric tests for the patients from family FR1 were normal, the two compound missense mutations might be responsible for RP without hearing loss.

![The sequence alignment portion of **A**: Laminin epidermal growth factor (EGF)-like domain and **B**: Fibronectin type 3 domain, in the long usherin isoform from different species. Both Cys934 (C934) and Trp2744 (W2744) are conserved during evolution. The arrows indicate the mutated residues in Usher syndrome type IIA (USH2A).](mv-v17-1537-f8){#f8}

Three different compound heterozygous mutations were identified in three families (F6, F7, and F8) with USH2 and all six mutations directly or indirectly resulted in premature termination of the USH2A translation. This is consistent with Dreyer et al. \[[@r25]\] previous observation that patients carrying compound heterozygous mutations (either two truncating or one truncating combined with one missense) in exon 22--72 presented the Usher type II phenotype. In contrast to the patients from the three USH2 families, the patients in FR1 carried two missense mutations. A recent study in a cohort of 272 Spanish patients with non-syndromic RP resulted in the identification of two mutant alleles of the *USH2A* gene in nine patients, with seven of them carrying either homozygous missense mutations or two heterozygous missense mutations \[[@r18]\]. In a large Chinese family, four patients carrying one truncating combined with one missense mutation (p.G1734R) exhibited RP with hearing loss, while the only person harboring the homozygous misense mutation (p.G1734R) presented RP without hearing loss \[[@r19]\]. However, this phenomenon was not observed in one Israeli family with three non-syndromic RP patients carrying one missense mutation and one truncating mutation \[[@r15]\].

As in our previous study \[[@r21]\], with the exception of one mutation (p.R626X), the other mutations identified in the current study were novel and were spread relatively evenly along the *USH2A* gene ([Figure 9](#f9){ref-type="fig"}). These results indicate that the mutation spectrum for the *USH2A* gene among Chinese or Asian patients differs from the mutation spectrum among European Caucasians. The common mutations, p. E767fs for USH2 and p.C759F for arRP in Caucasians, are not detected in Chinese and Japanese patients \[[@r12]-[@r14],[@r16],[@r18],[@r19],[@r21],[@r27]-[@r29]\].

![A schematic distribution showing the eight disease-causing mutations in the Usher syndrome type IIA (USH2A) isoform b protein domains identified in this study and in the five disease-causing mutations (blue characters) from a previous study \[[@r21]\]. Abbreviation: Laminin G-like domain (Lam GL); Laminin N-terminal (Lam NT); Laminin EGF-like domain (Lam EGF); Fibronectin type III (FN3); Laminin G domains (Lam G); Transmembrane region (TM); and PDZ-binding motif (PBM).](mv-v17-1537-f9){#f9}

In conclusion, our results further support previous indications that the mutations of the *USH2A* gene are also responsible for non-syndromic RP in Chinese patients. The mutation spectrum among Chinese patients appears to differ from that among European Caucasians.
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